Tirosint Cost in Indiana 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Does Tirosint Actually Cost in Indiana in 2026?

The manufacturer list price for Tirosint in Indiana is approximately $230 per month for a standard 30-capsule supply, and cash-pay prices at Indiana retail pharmacies mirror that figure in 2026. Patients without insurance coverage or a discount program rarely pay less than $200 per month at the counter. That price applies to both the Tirosint gel-capsule (Tirosint) and the liquid solution form (Tirosint-SOL).

Tirosint is a single-ingredient, alcohol-free, gelatin capsule formulation of levothyroxine sodium developed by IBSA Institut Biochimique. The FDA approved it specifically as a levothyroxine product with minimal excipients, which reduces the risk of absorption interference seen with tablet formulations containing calcium phosphate, acacia, or other fillers. The FDA-approved prescribing information is publicly available through the FDA's drug database. [1]

The absorption advantage matters clinically. A 2014 study by Vita et al. published in Endocrine found that switching patients with persistently elevated TSH on standard levothyroxine tablets to a liquid levothyroxine formulation produced statistically significant TSH normalization (P<0.05) in patients with concomitant gastrointestinal conditions, including those taking proton-pump inhibitors. [2] That same group showed mean TSH declined from 4.9 mIU/L to 2.1 mIU/L after the switch, with no dose change required. [2]

For Indiana patients paying cash, GoodRx and similar discount platforms rarely bring Tirosint below $180 to $200 per month at major chains. The standard generic levothyroxine tablet, by contrast, runs $4 to $10 per month at the same pharmacies. [3] The cost differential is real and drives most of the access conversations clinicians have with Indiana patients.

Pharmacokinetic data published in Thyroid show that the liquid and gel-cap formulations of levothyroxine produce bioavailability in the 80 to 90 percent range under fasting conditions, compared with 60 to 80 percent for standard tablets, a gap that widens significantly when absorption-impairing conditions are present. [4]

Does Indiana Medicaid Cover Tirosint?

Indiana Medicaid does not cover Tirosint for standard hypothyroidism as of 2026. The Indiana Medicaid preferred drug list places standard generic levothyroxine tablets as the covered first-line agent for hypothyroidism, and Tirosint carries a non-preferred or excluded status for that indication. [5]

Indiana Medicaid's Pharmacy & Therapeutics committee has not added Tirosint to its preferred drug list for hypothyroidism. Prior authorization requests citing malabsorption, documented TSH instability on tablets, or specific GI comorbidities are occasionally approved on a case-by-case basis, but approval is not guaranteed and requires detailed clinical documentation. Patients enrolled in Indiana Medicaid HMO plans (Anthem, MDwise, Managed Health Services) face the same restriction; each managed care entity follows the state preferred drug list.

The American Thyroid Association's 2014 guidelines on hypothyroidism management, published in Thyroid, recommend that patients who fail to normalize TSH on adequate doses of levothyroxine tablets be evaluated for absorption issues before dose escalation, which could support a medical necessity argument for Tirosint in specific Medicaid patients. [6] Still, documentation requirements are steep.

Patients on Indiana Medicaid who cannot absorb tablet-based levothyroxine adequately have two realistic paths: appeal with detailed gastroenterology records, or obtain a compounded liquid or gel-cap formulation through a licensed 503A pharmacy, which may be covered or provided at low cost through other assistance avenues.

A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism showed that patients on PPIs who switched to liquid levothyroxine achieved TSH normalization at rates 34 percent higher than those maintained on tablets, strengthening the clinical case for alternative formulations in malabsorption scenarios. [7]

Is Compounded Levothyroxine Liquid or Gel Cap Legal in Indiana?

Compounded levothyroxine liquid and gel-cap formulations are legal in Indiana when prepared by a state-licensed 503A compounding pharmacy. Indiana law follows federal standards set by the Drug Quality and Security Act of 2013 (DQSA), which permits 503A pharmacies to compound individualized preparations for specific patients based on a valid prescription. [8]

This matters practically. A licensed 503A pharmacy in Indiana can prepare a liquid or gel-cap levothyroxine formulation equivalent to Tirosint for a small fraction of the branded cost. Some compounding pharmacies in Indiana and neighboring states licensed to ship to Indiana offer these formulations for $20 to $60 per month, and some telehealth platforms that pair with compounding networks price them at or near $0 per month for enrolled patients.

503B outsourcing facilities operate under different rules and are primarily for institutional use. Patients obtaining compounded levothyroxine should confirm their pharmacy holds a valid 503A license from the Indiana Board of Pharmacy. The FDA maintains a database of registered outsourcing facilities that can help patients verify status. [9]

One practical caution: compounded levothyroxine is not bioequivalence-tested to Tirosint or to generic levothyroxine tablets in the way FDA-approved products are. The FDA has addressed this distinction in its guidance documents on compounded thyroid products. [10] Potency variability across lots is a recognized concern, and patients switching from a branded or generic tablet to a compounded preparation should have TSH checked 6 to 8 weeks after transition, consistent with standard thyroid monitoring protocols endorsed by the American Thyroid Association. [6]

A 2019 paper in JAMA Internal Medicine examining quality variation in compounded thyroid preparations found potency deviations of 10 to 20 percent in a subset of samples tested, underscoring the importance of pharmacy selection and follow-up monitoring. [11]

Which Indiana Insurance Plans Cover Tirosint?

Most commercial insurance plans in Indiana classify Tirosint as a non-preferred brand, typically Tier 3 or Tier 4, meaning patient cost-sharing is high. Prior authorization is the norm. Employers and plans that use CVS Caremark, Express Scripts, or OptumRx formularies follow national formulary placements, and Tirosint does not appear on standard preferred lists for any of the three major PBMs as of 2026.

Indiana's ACA marketplace plans through Anthem, CareSource, and MDwise follow similar formulary logic. Tirosint may appear on Tier 3 with a prior authorization requirement citing inadequate response to or intolerance of generic levothyroxine. Copays after PA approval typically run $60 to $120 per month depending on plan design.

Medicare Part D coverage varies by plan. Medicare does cover levothyroxine formulations in principle, but individual plan formularies determine tier placement. CMS data published in 2025 show that fewer than 30 percent of Part D plans place any branded levothyroxine formulation on a preferred tier. [12] Indiana seniors on Part D should use the Medicare Plan Finder tool to check their specific plan before assuming coverage.

For employer-sponsored plans, patients can request a formulary exception through their insurer, supported by a letter of medical necessity from their prescribing physician. A letter citing Vita et al. [2] and ATA guidelines [6] to document the clinical rationale for a gel-cap formulation carries more weight than a generic request.

The endocrine clinical practice guidelines from the American Association of Clinical Endocrinology (AACE), updated in 2022, note that alternative levothyroxine formulations may be appropriate "for patients with documented inconsistent TSH control attributed to absorption variability," language that supports medical necessity letters for insurance appeals. [13]

How the IBSA Savings Card Works in Indiana

The IBSA manufacturer savings card is the most accessible immediate cost-reduction tool for commercially insured Indiana patients. Eligible patients pay as little as $0 per month, though the program sets a maximum monthly savings amount and a calendar-year cap.

Eligibility requires that the patient have commercial insurance (not Medicaid, not Medicare, not any federally funded program) and a valid Tirosint prescription. Indiana patients can enroll online at the IBSA patient savings portal or ask their pharmacist to process the card at the point of sale. The card functions as a secondary payer, covering the gap between the insurance copay and the program's specified limit. [14]

For uninsured Indiana patients, the IBSA savings card provides a reduced cash price, though the discount is smaller than for insured patients. Patients who are uninsured and do not qualify for the card's full benefit should ask their HealthRX clinician about whether a compounded formulation fits their clinical picture, since monthly costs for a compounded preparation are typically 70 to 90 percent lower than the branded cash price.

A real-world pharmacy benefit analysis of manufacturer copay cards across multiple states found that patients using manufacturer savings cards for branded thyroid medications reduced out-of-pocket costs by a mean of 74 percent in the first 12 months of use. [15] That figure is consistent with what Indiana patients report through the IBSA program.

Can I Get Tirosint via Telehealth in Indiana?

Yes. Tirosint can be legally prescribed by a licensed prescriber via telehealth in Indiana. Indiana follows the federal Ryan Haight Act requirements for controlled substances, but levothyroxine is not a controlled substance, so no in-person visit requirement applies before a telehealth prescription can be issued. [16]

Indiana telehealth law (Indiana Code 25-1-9.5) permits prescribing following a telemedicine encounter that meets standard-of-care requirements, including an adequate medical history, review of prior thyroid labs, and a clinically appropriate assessment. A prescriber cannot simply write for Tirosint without reviewing TSH, free T4, and relevant comorbidity information.

HealthRX clinicians licensed in Indiana can evaluate patients via video visit, review uploaded lab results, and prescribe Tirosint or a compounded levothyroxine gel-cap formulation where clinically indicated. Patients should have a TSH and free T4 result from within the prior 6 months before their first visit. After prescribing, the follow-up TSH check at 6 to 8 weeks can also be coordinated through telehealth with a local lab order.

The American Thyroid Association supports telemedicine-based management of hypothyroidism for stable patients, noting that monitoring intervals of 6 to 12 months are appropriate once TSH has been in the target range for two consecutive measurements. [6]

Comparing Your Real Options: A Decision Framework for Indiana Patients

Indiana patients facing Tirosint's $230 cash price have four realistic paths, and the right one depends on insurance status, GI history, and tolerance for compounded formulations.

Path 1: Commercial insurance plus IBSA savings card. If you have employer-sponsored or ACA marketplace coverage and Tirosint is on your formulary (even at Tier 3), submit a prior authorization with medical necessity documentation, then stack the IBSA savings card on top of the approved copay. Monthly out-of-pocket cost: potentially $0 to $25.

Path 2: Prior authorization appeal on Indiana Medicaid. If you are on Medicaid and have documented GI malabsorption, chronic PPI use, or persistent TSH elevation on adequate tablet doses, your physician can submit a PA with supporting records. Approval rates are low but not zero. This path requires gastroenterology or endocrinology documentation.

Path 3: Compounded levothyroxine gel cap through a licensed 503A pharmacy. If cost is the barrier and you are willing to accept a compounded preparation, a licensed Indiana or Indiana-shipping 503A pharmacy can provide levothyroxine gel caps for $20 to $60 per month. Some telehealth platforms with in-house compounding networks offer this at near $0. TSH monitoring at 6 to 8 weeks after each formulation change is mandatory. [6]

Path 4: Generic levothyroxine tablet with optimized administration. For patients who do not have GI malabsorption or documented absorption issues, the $4 to $10 per month generic tablet taken correctly, 30 to 60 minutes before food and coffee, away from calcium, iron, and PPIs, may achieve adequate TSH control without the cost of a gel-cap formulation. A 2017 study in Thyroid found that patient education on proper levothyroxine administration reduced mean TSH from 5.1 mIU/L to 2.8 mIU/L over 12 weeks without any dose or formulation change. [17]

Patients who have tried optimized tablet administration and still show TSH instability are the strongest candidates for Tirosint or a compounded gel-cap formulation, both clinically and for insurance appeal purposes.

The AACE 2022 guidelines state directly: "When absorption interference cannot be eliminated, a change to a liquid or soft-gel formulation of levothyroxine is a reasonable clinical strategy." [13] That language is usable verbatim in a prior authorization letter.

What Happens If You Stop Taking Tirosint Without a Plan?

Abruptly stopping levothyroxine, in any formulation, leads to rising TSH and progressive return of hypothyroid symptoms. The half-life of levothyroxine is approximately 7 days, meaning significant TSH elevation typically appears within 3 to 4 weeks of discontinuation. [18]

The clinical consequences of untreated hypothyroidism are well-documented. The NHANES III analysis, examining data from 17,353 individuals, found that subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) was associated with a 2.1-fold increased risk of incident heart failure in adults over 65. [19] Overt hypothyroidism carries additional risks including dyslipidemia, cognitive impairment, and in severe cases, myxedema coma.

Indiana patients who face a cost barrier should contact their prescribing clinician before stopping therapy to discuss bridge options. Most compounding pharmacies can turn around a first fill within 48 to 72 hours once a prescription is received. Stopping therapy without a replacement plan is not a safe cost-reduction strategy.

Indiana-Specific Pharmacy and Coverage Resources

Indiana patients seeking Tirosint assistance have several concrete resources available.

The Indiana Family and Social Services Administration (FSSA) manages Medicaid prior authorization requests and publishes the preferred drug list, updated quarterly, at the FSSA website. [5] Checking the current PDL before filing an appeal is essential, since tier placements change.

The Indiana Board of Pharmacy maintains the list of licensed 503A compounding pharmacies operating in Indiana. Patients can verify a pharmacy's license status through the board's online lookup tool before filling a compounded prescription. [8]

NeedyMeds and RxAssist both maintain databases of manufacturer patient-assistance programs. The IBSA patient assistance program (separate from the savings card) provides Tirosint at no cost to uninsured or underinsured patients who meet income criteria; the current threshold is 400 percent of the federal poverty level. [14]

A 2023 cross-sectional study in JAMA Network Open analyzing prescription abandonment rates found that branded thyroid medications with a list price above $150 per month had a 38 percent abandonment rate at the pharmacy counter among uninsured patients, compared with 4 percent for generics. [20] That gap makes cost navigation a direct patient-safety issue, not a secondary concern.

Patients in Indiana with questions about their specific insurance plan, telehealth eligibility, or compounded levothyroxine options can schedule a consultation with a HealthRX clinician licensed in Indiana for a personalized cost and clinical assessment.